Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Probucol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 1.00 |
| ▸ | VCAM1 | P19320 | 13/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probucol SCHEMBL5143451 | 1.00 | HPN (1.00) | HPNMAPTALOX15SIRT5VCAM1 | |
| Probucol SCHEMBL4620631 | 0.98 | ALOX15 (0.95) | HPNMAPTALOX15SIRT5VCAM1 | |
| Probucol SCHEMBL8344652 | 0.98 | ALOX15 (0.95) | HPNMAPTALOX15SIRT5VCAM1 | |
| SCHEMBL12791592 | 0.92 | ALOX15 (0.84) | HPNMAPTALOX15SIRT5VCAM1 | |
| SCHEMBL4985953 | 0.92 | HPN (0.84) | HPNMAPTALOX15SIRT5VCAM1 | |
| SCHEMBL4996488 | 0.90 | ALOX15 (0.81) | HPNMAPTALOX15SIRT5VCAM1 | |
| Probucol SCHEMBL8344272 | 0.90 | HPN (0.81) | HPNMAPTALOX15SIRT5VCAM1 | |
| SCHEMBL9506457 | 0.88 | HPN (0.79) | HPNMAPTALOX15SIRT5VCAM1 | |
| SCHEMBL4983541 | 0.88 | ALOX15 (0.78) | HPNMAPTALOX15SIRT5VCAM1 | |
| SCHEMBL15344011 | 0.87 | ALOX15 (0.75) | HPNMAPTALOX15SIRT5VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 33126 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075472-A | Vitexin-probucol self-assembled nanoparticle and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| EP-4702995-A1 | DRUG COATING AND MEDICAL DEVICE COMPRISING SAME, SYSTEM, AND PREPARATION METHOD | Beijing Salubris Medtech Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| US-4970221-A | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same | E. R. SQUIBB & SONS, INC. (US) | 1990-11-13 | — | — | US | claimed |
| EP-0373507-A1 | Combination of an HMG CoA reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-06-20 | — | — | EP | claimed |
| US-4861443-A | Process for preparing 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol) by electrocatalysis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-29 | — | — | US | claimed |
| EP-0292660-A2 | Alkylidenedithiobis (substituted) phenols for inhibiting interleukin-1 release and for alleviating interleukin-1 mediated conditions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-11-30 | — | — | EP | claimed |
| EP-0277491-A1 | Process for preparing 4,4'-isopropylidenedithio-bis(2,6-di-tertiary butylphenol) by electrocatalysis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-10 | — | — | EP | claimed |
| US-4734527-A | ZINC AND LEAD CATALYST | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-03-29 | — | — | US | claimed |
| EP-0254272-A2 | The use of probucol for preventing and treating heart diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-01-27 | — | — | EP | claimed |
| US-4719237-A | Cardiac antiarrythmic method employing probucol | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-01-12 | — | — | US | claimed |
| EP-0212310-A2 | Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-03-04 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |